Password-BoardProtocol-2-3-2021

Protocol No 2 and 3 2020. March 18th 2020 (unsigned)

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.